Loading
A phase 3 trial of Taletrectinib, Crizotinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., now recruiting.
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT06564324 by Nuvation Bio Inc., with 194 participants planned, started 2024-11-27 and due to reach its primary completion in 2029-01. Interventions recorded: Taletrectinib, Crizotinib. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Nuvation Bio, ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib.
Shares ROS1-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/